Literature DB >> 16617317

BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma.

M Abe, S Kido, M Hiasa, A Nakano, A Oda, H Amou, T Matsumoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16617317     DOI： 10.1038/sj.leu.2404228

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  42 in total

Review 1.  Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma.

Authors:  Masahiro Abe
Journal:  Int J Hematol       Date:  2011-10-18       Impact factor: 2.490

Review 2.  Here, There, and Anywhere? Arguments for and against the Physical Plasma Cell Survival Niche.

Authors:  Joel R Wilmore; David Allman
Journal:  J Immunol       Date:  2017-08-01       Impact factor: 5.422

Review 3.  Novel therapeutic targets in myeloma bone disease.

Authors:  S L Webb; C M Edwards
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 4.  New roles for the BLyS/BAFF family in antigen-experienced B cell niches.

Authors:  Radhika Goenka; Jean L Scholz; Vishal J Sindhava; Michael P Cancro
Journal:  Cytokine Growth Factor Rev       Date:  2014-01-10       Impact factor: 7.638

5.  FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.

Authors:  Y Li; M N Bouchlaka; J Wolff; K M Grindle; L Lu; S Qian; X Zhong; N Pflum; P Jobin; B S Kahl; J C Eickhoff; S M Wuerzberger-Davis; S Miyamoto; C J Thomas; D T Yang; C M Capitini; L Rui
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

6.  Classical and/or alternative NF-kappaB pathway activation in multiple myeloma.

Authors:  Yulia N Demchenko; Oleg K Glebov; Adriana Zingone; Jonathan J Keats; P Leif Bergsagel; W Michael Kuehl
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

Review 7.  Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.

Authors:  A Sabokbar; D J Mahoney; F Hemingway; N A Athanasou
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

8.  Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4-VCAM-1 adhesion and macrophage inflammatory protein-1alpha and MIP-1beta production.

Authors:  Masahiro Abe; Kenji Hiura; Shuji Ozaki; Shinsuke Kido; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

9.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

10.  Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study.

Authors:  J-F Rossi; J Moreaux; D Hose; G Requirand; M Rose; V Rouillé; I Nestorov; G Mordenti; H Goldschmidt; A Ythier; B Klein
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.